trending Market Intelligence /marketintelligence/en/news-insights/trending/ufxznsguuqie62c6mqibbq2 content esgSubNav
In This List

J&J, Novartis, Astellas invest in Twentyeight-Seven Therapeutics

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Dealmaking slumps; rate hikes hammer gold; transaction banking revenues jump

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future


J&J, Novartis, Astellas invest in Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics said it raised $65 million in a round of financing that saw the participation of Novartis AG, Johnson & Johnson and Astellas Pharma Inc.

The Cambridge, Mass.-based biotechnology company, which is developing treatments for cancer, said the series A financing was co-led by MPM Capital LLC and Novartis Venture Funds and saw the participation of Johnson & Johnson Innovation - JJDC Inc., Vertex Ventures HC, Astellas Venture Management LLC, and Longwood Fund.

The funds will be used to advance the company's lead program, Let-7, for treating cancer. The program targets certain proteins in the body to increase tumor suppression.

In separate news, the company said it appointed Shomir Ghosh as its chief scientific officer. Ghosh, who has 25 years of scientific research, drug discovery and development experience, was most recently the chief scientific officer and a founding scientist of IFM Therapeutics Inc.

Twentyeight-Seven also said its president and CEO, Kazumi Shiosaki, will join the company's board in addition to certain investors: Luke Evnin, managing director and co-founder of MPM; Briggs Morrison, executive partner at MPM and CEO of Syndax Pharmaceuticals Inc.; Carolyn Ng, principal at Vertex Ventures; and Michal Silverberg, Novartis Venture Fund's managing director.